Analyst Price Target is $2.50
▲ +1,223.45% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for CohBar in the last 3 months. The average price target is $2.50, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 1,223.45% upside from the last price of $0.19.
Current Consensus is
Buy
The current consensus among 1 investment analysts is to buy stock in CohBar. This Buy consensus rating has held steady for over two years.
CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes, acute respiratory distress syndrome, cancer, and cardiovascular diseases, such as Alzheimer's disease. Its lead clinical candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of NASH and obesity. The company's preclinical programs include CB5138 analogs for fibrotic diseases; and CB5064 analogs for COVID-19 associated ARDS. CohBar, Inc. was incorporated in 2007 and is headquartered in Menlo Park, California.
Read More